Industry

Treatment with KIF18A inhibitor led to substantial, dose-dependent inhibition of tumor growth in multiple tumor models, with no effect on normal cells KIF18A inhibitor on track to enter the clinic in 2H 2023 NEW YORK–(BUSINESS WIRE)–Volastra Therapeutics, an oncology company focused on exploiting chromosomal instability (CIN), today announced new data from its lead program, a … [Read more…]

National medical group files lawsuit, urging health insurer to pay its bills and fairly reimburse clinicians providing life-saving emergency care to patients across the country NASHVILLE, Tenn.–(BUSINESS WIRE)–Envision Healthcare, a leading national medical group, filed suit against UnitedHealthcare Services, Inc. and UnitedHealthcare Insurance Company (“United”) in U.S. federal court in Tennessee. The suit claims that … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “US Colorectal Cancer Market and Competitive Landscape – 2022” report has been added to ResearchAndMarkets.com’s offering. The report provides comprehensive insights into Colorectal Cancer pipeline products, Colorectal Cancer epidemiology, Colorectal Cancer market valuations and forecast, Colorectal Cancer drugs sales and competitive landscape in the US. The research is classified into seven sections – … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “US Melanoma Market and Competitive Landscape – 2022” report has been added to ResearchAndMarkets.com’s offering. The report provides comprehensive insights into Melanoma pipeline products, Melanoma epidemiology, Melanoma market valuations and forecast, Melanoma drugs sales and competitive landscape in the US. The research is classified into seven sections – Melanoma treatment options, pipeline products, … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Doxorubicin Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Drug Formulation, Application, and Distribution Channel” report has been added to ResearchAndMarkets.com’s offering. The global doxorubicin market is projected to reach US$ 1,983.40 million by 2028 from US$ 1,390.64 million in 2022; it is expected to register a CAGR of 6.1% … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Cardiac Markers Rapid Tests and POC Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update” report has been added to ResearchAndMarkets.com’s offering. This report provides comprehensive information about the Cardiac Markers Rapid Tests & POC pipeline products with comparative analysis of the products at various … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Biostimulants Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product, Mode of Application, and Crop Type” report has been added to ResearchAndMarkets.com’s offering. The biostimulants market is expected to grow from US$ 3,112.49 million in 2022 to US$ 5,796.94 million by 2028; it is estimated to grow at a CAGR … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Aseptic Processing Global Market Report 2022” report has been added to ResearchAndMarkets.com’s offering. The global aseptic processing market is expected to grow from $68.62 billion in 2021 to $72.40 billion in 2022 at a compound annual growth rate (CAGR) of 5.52%. The aseptic processing market is expected to grow to $87.38 billion in … [Read more…]

Tenalisib (RP6530, selective dual PI3K d/γ inhibitor with additional SIK3 inhibitory activity) showed encouraging results with a clinical benefit rate (CBR) of 57.5% from an ongoing phase II trial in patients with locally advanced or metastatic HR+/HER2- breast cancer (mBC) RP12146, Rhizen’s next generation PARP1/2 inhibitor concludes dose escalation phase with a favorable safety profile … [Read more…]

PORTLAND, Ore.–(BUSINESS WIRE)–Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both rheumatology and endocrinology, today announced that the first patient has been dosed in a phase 2 clinical trial (NCT number: NCT05436652) of prednisolone in combination with SPI-62, Sparrow’s potent and selective investigational HSD-1 inhibitor, for the … [Read more…]